These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 10910143)

  • 1. Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease.
    Heslop H; Rooney C; Brenner M; Krance R; Carrum G; Gahn B; Bollard C; Khan S; Gee A; Popat U; Gresik M; Przepiorka D; Kuehnle I; Grilley B
    Hum Gene Ther; 2000 Jul; 11(10):1465-75. PubMed ID: 10910143
    [No Abstract]   [Full Text] [Related]  

  • 2. Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease.
    Roskrow MA; Rooney CM; Heslop HE; Brenner MK; Krance RA; Gresik MV; McClain K; Aguilar LK; Grilley B; Rob E; Carrum G
    Hum Gene Ther; 1998 May; 9(8):1237-50. PubMed ID: 9625264
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy for Hodgkin's disease.
    Rooney CM; Bollard C; Huls MH; Gahn B; Gottschalk S; Wagner HJ; Anderson R; Prentice HG; Brenner MK; Heslop HE
    Ann Hematol; 2002; 81 Suppl 2():S39-42. PubMed ID: 12611071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of neomycin-resistance-gene-marked EBV-specific cytotoxic T lymphocytes to recipients of mismatched-related or phenotypically similar unrelated donor marrow grafts.
    Heslop HE; Brenner MK; Rooney C; Krance RA; Roberts WM; Rochester R; Smith CA; Turner V; Sixbey J; Moen R
    Hum Gene Ther; 1994 Mar; 5(3):381-97. PubMed ID: 8018749
    [No Abstract]   [Full Text] [Related]  

  • 5. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient.
    Basso S; Zecca M; Calafiore L; Rubert L; Fiocchi R; Paulli M; Quartuccio G; Guido I; Sebastiani R; Croci GA; Beschi C; Nardiello I; Ginevri F; Cugno C; Comoli P
    Pediatr Transplant; 2013 Nov; 17(7):E168-73. PubMed ID: 23992468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes in EBV-related diseases].
    Kuzushima K
    Rinsho Ketsueki; 2000 Jun; 41(6):487-90. PubMed ID: 10921347
    [No Abstract]   [Full Text] [Related]  

  • 8. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant.
    Regn S; Raffegerst S; Chen X; Schendel D; Kolb HJ; Roskrow M
    Bone Marrow Transplant; 2001 Jan; 27(1):53-64. PubMed ID: 11244438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of gene marking in bone marrow transplantation.
    Heslop HE; Rooney CM; Rill DR; Krance RA; Brenner MK
    Cancer Detect Prev; 1996; 20(2):108-13. PubMed ID: 8706035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
    Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
    Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
    Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
    Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term remission after nonmyeloablative allogeneic bone marrow transplantation in a relapsed Hodgkin lymphoma patient with CNS involvement].
    Shimura H; Imai Y; Ishiyama M; Yoshinaga K; Shiseki M; Mori N; Teramura M; Motoji T
    Rinsho Ketsueki; 2012 Dec; 53(12):1991-6. PubMed ID: 23318964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.
    Papadopoulos EB; Ladanyi M; Emanuel D; Mackinnon S; Boulad F; Carabasi MH; Castro-Malaspina H; Childs BH; Gillio AP; Small TN
    N Engl J Med; 1994 Apr; 330(17):1185-91. PubMed ID: 8093146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microchimerism detection by human leucocyte antigen-specific quantitative-polymerase chain reaction analysis in recipients of allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes.
    Lucas KG; Nelson JL; Erickson TD; Sun Q
    Br J Haematol; 2005 May; 129(3):443-4. PubMed ID: 15842671
    [No Abstract]   [Full Text] [Related]  

  • 15. Epstein-Barr virus-specific cytotoxic T cell response in cardiac transplant recipients.
    Kyaw-Tanner MT; Esmore D; Burrows SR; Benson EM; Sculley TB
    Transplantation; 1994 Jun; 57(11):1611-7. PubMed ID: 8009596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease.
    Okamura T; Kishimoto T; Inoue M; Honda M; Yamashita N; Wakiguchi H; Yagita M; Hosoi G; Sako M; Yasui M; Yagi K; Kawa K
    Bone Marrow Transplant; 2003 Jan; 31(2):105-11. PubMed ID: 12621491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
    Lucas KG; Salzman D; Garcia A; Sun Q
    Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EBV lytic infection enhances transformation of B-lymphocytes infected with EBV in the presence of T-lymphocytes.
    Katsumura KR; Maruo S; Takada K
    J Med Virol; 2012 Mar; 84(3):504-10. PubMed ID: 22246839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of DiGeorge anomaly with EBV-induced lymphoma by transplantation of organ-cultured thymus and Epstein-Barr-specific cytotoxic T lymphocytes.
    Hong R; Shen V; Rooney C; Hughes DP; Smith C; Comoli P; Zhang L
    Clin Immunol; 2001 Jan; 98(1):54-61. PubMed ID: 11141327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
    Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
    Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.